

## PHARMANUTRA S.P.A.: ALESCO SUBSIDIARY OBTAINS PATENT FOR THE NEW SUCROSOMIAL® BERBERINE

***The new license joins 18 other patents already held by the Group and represents the first application of Sucrosomial® Technology to a plant extract.***

Pisa, 25 October 2021 – [PharmaNutra S.p.A.](#) (MTA; Ticket PHN) gives notice that its subsidiary Alesco S.r.l., which specialises in the development, production and distribution of raw materials (active ingredients) for the pharmaceuticals and nutraceuticals market, has been granted a patent by the Italian Patents & Trademarks Office for a new functional ingredient, Sucrosomial® Berberine (UltraBerb™). The patent is valid until November 2039 (number 102019000020290).

This is a particularly important step for the PharmaNutra Group company, as it represents the first application of Sucrosomial® Technology to a new element not related to minerals, the area for which the technology was originally developed.

*“With the new Sucrosomial® Berberine we have successfully applied our know-how to plant extracts for the first time. The patent marks a new departure for our Sucrosomial® Technology, as its application to this new type of active ingredient represents a significant step forward in the development of a new scientific research area and new products,”* commented **PharmaNutra Group’s Chairman Andrea Lacorte**.

*“The patent is a new strategic asset we shall be developing and investing in,”* added **Carlo Volpi, Chairman of Alesco S.r.l.** *“It is yet another confirmation of the outstanding work of our Scientific Department headed by Dr. Germano Tarantino.”*

Berberine is a plant alkaloid extracted from plants in the genus *Berberis*, with many benefits on fat metabolism and protection of the cardiovascular system. As with minerals, the application of the Sucrosomial® Technology improves its tolerability and absorption, making it a useful solution in formulations for the control of cholesterol and blood sugar.

## PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, established in 2003, develops unique dietary supplements and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar® brand. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 120 published papers. In Italy, sales are conducted through a network of more than 160 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies all over the country. International sales in more than 50 countries are managed through 37 partners selected from top pharmaceutical companies. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa  
Tel. +39 050 7846500  
[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan  
Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)